Cullinan Therapeutics, Inc. - Common Stock — 四半期財務統計 (NASDAQ:CGEM) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

営業活動によるキャッシュフロー -36.63 M-43.16 M-57.61 M-36.88 M-38.11 M-46.05 M -178.64 M 投資活動によるキャッシュフロー 15.96 M36.8 M53.4 M67.39 M22.39 M32.41 M 175.6 M 財務活動によるキャッシュフロー 1.58 M0373 K0715 K380 K 1.47 M フリーキャッシュフロー -36.63 M-43.16 M-57.61 M-36.88 M-38.12 M-46.05 M -178.65 M

ニュース

Will Health Benefits Weakness Drag Elevance's Q1 Earnings?

Stifel、自己免疫疾患の進展を受けてCullinan Oncologyの目標株価を引き上げ

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

グッゲンハイムがカリナン・オンコロジー株を「買い」で開始、目標価格30ドル

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

カリナン・セラピューティクス、主要自己免疫疾患プログラムのデータ公表を計画